DLB
MCID: DMN031
MIFTS: 67

Dementia, Lewy Body (DLB)

Categories: Genetic diseases, Mental diseases, Rare diseases

Aliases & Classifications for Dementia, Lewy Body

MalaCards integrated aliases for Dementia, Lewy Body:

Name: Dementia, Lewy Body 58 26 13
Lewy Body Dementia 58 12 54 26 55 76 38 30 6 15 41 17
Lewy Body Disease 12 54 26 56 44 45 74
Diffuse Lewy Body Disease 58 12 54 26 76
Dementia with Lewy Bodies 12 77 26 55 15
Dlb 58 54 26 76
Autosomal Dominant Diffuse Lewy Body Disease 54 74
Diffuse Lewy Body Disease with Gaze Palsy 76
Lewy Body Variant of Alzheimer Disease 76
Dementia, Lewy Body, Susceptibility to 6
Lewy Body Dementia, Susceptibility to 58
Senile Dementia of the Lewy Body Type 12
Dementia of the Lewy Body Type 26
Lewy Body Type Senile Dementia 76
Dysphasic Dementia Hereditary 76
Cortical Lewy Body Disease 76
Dementia Lewy Body 76
Lewy Bodies 30
Lbd 26

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant

Miscellaneous:
onset in the sixth or seventh decades
phenotypic overlap with parkinson disease
allelic disorder to parkinson disease-1 (park1, )


HPO:

33
dementia, lewy body:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:12217
OMIM 58 127750
KEGG 38 H00066
ICD9CM 36 331.82
MeSH 45 D020961
NCIt 51 C84826
SNOMED-CT 69 80098002
ICD10 34 G31.83

Summaries for Dementia, Lewy Body

MedlinePlus : 44 What is Lewy body dementia (LBD)? Lewy body dementia (LBD) is one of the most common types of dementia in older adults. Dementia is a loss of mental functions that is severe enough to affect your daily life and activities. These functions include Memory Language skills Visual perception (your ability to make sense of what you see) Problem solving Trouble with everyday tasks The ability to focus and pay attention What are the types of Lewy body dementia (LBD)? There are two types of LBD: dementia with Lewy bodies and Parkinson's disease dementia. Both types cause the same changes in the brain. And, over time, they can cause similar symptoms. The main difference is in when the cognitive (thinking) and movement symptoms start. Dementia with Lewy bodies causes problems with thinking ability that seem similar to Alzheimer's disease. Later, it also causes other symptoms, such as movement symptoms, visual hallucinations, and certain sleep disorders. It also causes more trouble with mental activities than with memory. Parkinson's disease dementia starts as a movement disorder. It first causes the symptoms of Parkinson's disease: slowed movement, muscle stiffness, tremor, and a shuffling walk. Later on, it causes dementia. What causes Lewy body dementia (LBD)? LBD happens when Lewy bodies build up in parts of the brain that control memory, thinking, and movement. Lewy bodies are abnormal deposits of a protein called alpha-synuclein. Researchers don't know exactly why these deposits form. But they do know that other diseases, such as Parkinson's disease, also involve a build-up of that protein. Who is at risk for Lewy body dementia (LBD)? The biggest risk factor for LBD is age; most people who get it are over age 50. People who have a family history of LBD are also at higher risk. What are the symptoms of Lewy body dementia (LBD)? LBD is a progressive disease. This means that the symptoms start slowly and get worse over time. The most common symptoms include changes in cognition, movement, sleep, and behavior: Dementia, which is a loss of mental functions that is severe enough to affect your daily life and activities Changes in concentration, attention, alertness, and wakefulness. These changes usually happen from day to day. But sometimes they can also happen throughout the same day. Visual hallucinations, which means seeing things that are not there Problems with movement and posture, including slowness of movement, difficulty walking, and muscle stiffness. These are called parkinsonian motor symptoms. REM sleep behavior disorder, a condition in which a person seems to act out dreams. It may include vivid dreaming, talking in one's sleep, violent movements, or falling out of bed. This may be the earliest symptom of LBD in some people. It can appear several years before any other LBD symptoms. Changes in behavior and mood, such as depression, anxiety, and apathy (a lack of interest in normal daily activities or events) In the early stages of LBD, symptoms can be mild, and people can function fairly normally. As the disease gets worse, people with LBD need more help due to problems with thinking and movement. In the later stages of the disease, they often cannot care for themselves. How is Lewy body dementia (LBD) diagnosed? There isn't one test that can diagnose LBD. It is important to see an experienced doctor to get a diagnosis. This would usually be specialist such as a neurologist. The doctor will Do a medical history, including taking a detailed account of the symptoms. The doctor will talk to both the patient and caregivers. Do physical and neurological exams Do tests to rule out other conditions that could cause similar symptoms. These could include blood tests and brain imaging tests. Do neuropsychological tests to evaluate memory and other cognitive functions LBD can be hard to diagnose, because Parkinson's disease and Alzheimer's disease cause similar symptoms. Scientists think that Lewy body disease might be related to these diseases, or that they sometimes happen together. It's also important to know which type of LBD a person has, so the doctor can treat that type's particular symptoms. It also helps the doctor understand how the disease will affect the person over time. The doctor makes a diagnosis based on when certain symptoms start: If cognitive symptoms start within a year of movement problems, the diagnosis is dementia with Lewy bodies If cognitive problems start more than a year after the movement problems, the diagnosis is Parkinson's disease dementia What are the treatments for Lewy body dementia (LBD)? There is no cure for LBD, but treatments can help with the symptoms: Medicines may help with some of the cognitive, movement, and psychiatric symptoms Physical therapy can help with movement problems Occupational therapy may help find ways to more easily do everyday activities Speech therapy may help with swallowing difficulties and trouble speaking loudly and clearly Mental health counseling can help people with LBD and their families learn how to manage difficult emotions and behaviors. It can also help them plan for the future. Music or art therapy may reduce anxiety and improve well-being Support groups can also be helpful for people with LBD and their caregivers. Support groups can give emotional and social support. They are also a place where people can share tips about how to deal with day-to-day challenges. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Dementia, Lewy Body, also known as lewy body dementia, is related to parkinson disease 2, autosomal recessive juvenile and parkinson disease 3, autosomal dominant, and has symptoms including seizures, tremor and back pain. An important gene associated with Dementia, Lewy Body is SNCA (Synuclein Alpha), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Donepezil and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are dementia and visual hallucinations

Disease Ontology : 12 A dementia that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities.

Genetics Home Reference : 26 Dementia with Lewy bodies is a nervous system disorder characterized by a decline in intellectual function (dementia), a group of movement problems known as parkinsonism, visual hallucinations, sudden changes (fluctuations) in behavior and intellectual ability, and acting out dreams while asleep (REM sleep behavior disorder). This condition typically affects older adults, most often developing between ages 50 and 85. The life expectancy of individuals with dementia with Lewy bodies varies; people typically survive about 5 to 7 years after they are diagnosed.

NIH Rare Diseases : 54 Lewy body dementia is one of the most common forms of progressive dementia. People affected by this condition may experience a variety of symptoms such as changes in alertness and attention; hallucinations; problems with movement and posture; muscle stiffness; confusion; and/or memory loss. Although the exact cause of Lewy body dementia is poorly understood, symptoms are thought to result when clumps of a protein called alpha-synuclein ("Lewy bodies") accumulate in the brain. Lewy body dementia usually occurs sporadically in people with no family history of the condition. Rarely, more than one family member may be affected. There is currently no cure for Lewy body dementia; however, medications may be available to help manage the associated symptoms.

OMIM : 58 Dementia with Lewy bodies (DLB) is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Pathologically, Lewy bodies are present in a pattern more widespread than usually observed in Parkinson disease (see PD; 168600). Alzheimer disease (AD; 104300)-associated pathology and spongiform changes may also be seen (McKeith et al., 1996; Mizutani, 2000; McKeith et al., 2005). (127750)

NINDS : 55 Dementia with Lewy bodies (DLB) is one of the most common types of progressive dementia. The central features of DLB include progressive cognitive decline, “fluctuations” in alertness and attention, visual hallucinations, and parkinsonian motor symptoms, such as slowness of movement, difficulty walking, or rigidity.  People may also suffer from depression.  The symptoms of DLB are caused by the build-up of Lewy bodies – accumulated bits of alpha-synuclein protein -- inside the nuclei of neurons in areas of the brain that control particular aspects of memory and motor control.  Researchers don’t know exactly why alpha-synuclein accumulates into Lewy bodies or how Lewy bodies cause the symptoms of DLB, but they do know that alpha-synuclein accumulation is also linked to Parkinson's disease, multiple system atrophy, and several other disorders, which are referred to as the "synucleinopathies." The similarity of symptoms between DLB and Parkinson’s disease, and between DLB and Alzheimer’s disease, can often make it difficult for a doctor to make a definitive diagnosis. In addition, Lewy bodies are often also found in the brains of people with Parkinson's and Alzheimer’s diseases.  These findings suggest that either DLB is related to these other causes of dementia or that an individual can have both diseases at the same time.  DLB usually occurs sporadically, in people with no known family history of the disease. However, rare familial cases have occasionally been reported.

UniProtKB/Swiss-Prot : 76 Dementia Lewy body: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.

Wikipedia : 77 Dementia with Lewy bodies (DLB) is a type of dementia accompanied by changes in behavior, cognition and... more...

Related Diseases for Dementia, Lewy Body

Diseases related to Dementia, Lewy Body via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Related Disease Score Top Affiliating Genes
1 parkinson disease 2, autosomal recessive juvenile 32.4 LRRK2 PARK7 PRKN SNCA
2 parkinson disease 3, autosomal dominant 32.4 LRRK2 MAPT PARK7 PRKN SNCA SNCAIP
3 multiple system atrophy 1 32.2 LRRK2 MAPT PRKN RPS27A SLC6A3 SNCA
4 corticobasal degeneration 32.2 GBA LRRK2 MAPT RPS27A
5 perry syndrome 32.0 SLC18A2 SLC6A3 SNCA TH
6 posterior cortical atrophy 31.1 APOE MAPT
7 pure autonomic failure 30.7 ACHE MAOB SNCA TH
8 dysautonomia 30.5 GBA PRNP SNCA
9 aphasia 30.5 APOE APP MAPT PRNP SNCA
10 gaucher's disease 30.5 GBA PRKN SNCA
11 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 30.5 MAPT RPS27A
12 essential tremor 30.5 LRRK2 PRKN SLC6A3 SNCA
13 vascular dementia 30.4 ACHE APOE APP BCHE MAPT
14 alzheimer disease 2 30.4 APOE APP BCHE MAPT
15 rem sleep behavior disorder 30.4 ACHE LRRK2 RPS27A SLC6A3 SNCA
16 tremor 30.3 GBA LRRK2 MAPT PRKN SNCA
17 cerebral amyloid angiopathy, cst3-related 30.3 APOE APP MAPT PRNP
18 early-onset parkinson's disease 30.3 GBA LRRK2 PARK7 PRKN SNCA
19 creutzfeldt-jakob disease 30.3 APOE MAPT PRNP
20 cerebrovascular disease 30.3 ACHE APOE APP MAPT
21 neurodegeneration with brain iron accumulation 30.3 SNCA SNCB SNCG
22 semantic dementia 30.2 APOE MAPT RPS27A
23 pick disease of brain 30.2 APOE APP MAPT RPS27A SNCA
24 neuronal intranuclear inclusion disease 30.1 MAPT RPS27A SNCA
25 parkinson disease 10 30.1 LRRK2 PARK7 PRKN SNCA
26 psychotic disorder 30.0 CYP2D6 MAOB SLC18A2 SLC6A3
27 alzheimer disease 29.9 ACHE APOE APP BCHE MAOB MAPT
28 dementia 29.8 ACHE APOE APP BCHE GBA LRRK2
29 amyotrophic lateral sclerosis 1 29.7 APP MAOB MAPT PRNP RPS27A SNCA
30 frontotemporal dementia 29.7 ACHE APOE APP LRRK2 MAPT PRNP
31 supranuclear palsy, progressive, 1 29.5 ACHE APOE APP LRRK2 MAPT PARK7
32 movement disease 29.4 GBA LRRK2 MAPT PARK7 PRKN SLC18A2
33 parkinson disease, late-onset 28.5 ACHE APOE APP CYP2D6 GBA LRRK2
34 parkinson disease 1, autosomal dominant 12.1
35 myoclonic epilepsy of lafora 11.3
36 parkinson disease 4, autosomal dominant 11.2
37 parkinson disease 5, autosomal dominant 11.2
38 parkinson disease 19a, juvenile-onset 11.2
39 parkinson disease 8, autosomal dominant 11.0
40 parkinson disease 11, autosomal dominant 11.0
41 parkinson disease 13, autosomal dominant 11.0
42 parkinson disease 17 11.0
43 parkinson disease 18, autosomal dominant 11.0
44 parkinson disease 20, early-onset 11.0
45 parkinson disease 21 11.0
46 parkinson disease 22, autosomal dominant 11.0
47 parkinson disease 23, autosomal recessive early-onset 11.0
48 mitochondrial membrane protein-associated neurodegeneration 11.0
49 atypical autism 10.5
50 hereditary late-onset parkinson disease 10.4 GBA LRRK2 SNCA

Graphical network of the top 20 diseases related to Dementia, Lewy Body:



Diseases related to Dementia, Lewy Body

Symptoms & Phenotypes for Dementia, Lewy Body

Human phenotypes related to Dementia, Lewy Body:

33 (show all 6)
# Description HPO Frequency HPO Source Accession
1 dementia 33 HP:0000726
2 visual hallucinations 33 HP:0002367
3 parkinsonism 33 HP:0001300
4 lewy bodies 33 HP:0100315
5 delusions 33 HP:0000746
6 fluctuations in consciousness 33 HP:0007159

Symptoms via clinical synopsis from OMIM:

58
Neurologic Central Nervous System:
visual hallucinations
parkinsonism
delusions
fluctuations in consciousness
progressive dementia
more

Clinical features from OMIM:

127750

UMLS symptoms related to Dementia, Lewy Body:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, hallucinations, visual

MGI Mouse Phenotypes related to Dementia, Lewy Body:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 ACHE APOE APP GBA LRRK2 MAOB
2 homeostasis/metabolism MP:0005376 10.36 ACHE APOE APP BCHE GBA LRRK2
3 cellular MP:0005384 10.32 APOE APP GBA LRRK2 MAOB MAPT
4 growth/size/body region MP:0005378 10.27 ACHE APOE APP GBA MAPT PARK7
5 mortality/aging MP:0010768 10.21 ACHE APOE APP BCHE GBA LRRK2
6 nervous system MP:0003631 10.16 ACHE APOE APP GBA LRRK2 MAOB
7 cardiovascular system MP:0005385 10.15 APOE APP GBA LRRK2 MAPT PRKN
8 integument MP:0010771 10.1 APOE APP GBA LRRK2 MAPT PRKN
9 muscle MP:0005369 9.92 ACHE APOE APP MAPT PRKN PRNP
10 no phenotypic analysis MP:0003012 9.85 ACHE APOE APP LRRK2 MAPT PRKN
11 normal MP:0002873 9.65 APP GBA LRRK2 MAPT PRKN PRNP
12 taste/olfaction MP:0005394 9.02 APOE MAPT SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Dementia, Lewy Body

Drugs for Dementia, Lewy Body (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 4,Phase 3,Phase 2,Not Applicable 120014-06-4 3152
2
Modafinil Approved, Investigational Phase 4,Not Applicable 68693-11-8 4236
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
4
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
5
Iodine Approved, Investigational Phase 4 7553-56-2 807
6
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Corticosterone Experimental Phase 4 50-22-6 5753
9 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
11 Nootropic Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Central Nervous System Stimulants Phase 4,Not Applicable
14 Cytochrome P-450 CYP3A Inducers Phase 4,Not Applicable
15 Wakefulness-Promoting Agents Phase 4,Not Applicable
16 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
17 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
18 Dopamine Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Pharmaceutical Solutions Phase 4,Not Applicable
21 Calamus Phase 4
22 cadexomer iodine Phase 4
23 Fluorodeoxyglucose F18 Phase 4
24 Anti-Inflammatory Agents Phase 4
25 Analgesics Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
28 Antipyretics Phase 4
29 Analgesics, Opioid Phase 4
30 Central Nervous System Depressants Phase 4,Phase 3
31 Narcotic Antagonists Phase 4
32 Narcotics Phase 4
33
Galantamine Approved Phase 3 357-70-0 9651
34
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
35 Autonomic Agents Phase 3,Not Applicable
36 Protective Agents Phase 3,Not Applicable
37 Cardiotonic Agents Phase 3,Not Applicable
38 Sympathomimetics Phase 3,Not Applicable
39 Antipsychotic Agents Phase 3
40 Tranquilizing Agents Phase 3
41 Serotonin Antagonists Phase 3
42 Serotonin Agents Phase 3
43 Psychotropic Drugs Phase 3
44 Serotonin 5-HT2 Receptor Antagonists Phase 3
45
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
46 Dopamine agonists Phase 1, Phase 2,Phase 2,Not Applicable
47
Acetylcholine Approved, Investigational Not Applicable 51-84-3 187
48
Rivastigmine Approved, Investigational 123441-03-2 77991
49
Ethanol Approved 64-17-5 702
50
Hydroxocobalamin Approved 13422-51-0 15589840 11953898

Interventional clinical trials:

(show top 50) (show all 110)
# Name Status NCT ID Phase Drugs
1 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Completed NCT02345213 Phase 4 E2020;Placebo
2 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
3 Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
4 Longitudinal Imaging Biomarkers of Disease Progression in DLB Enrolling by invitation NCT03582488 Phase 4 18F-Flortaucipir
5 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
6 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
7 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
8 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
9 Donepezil Treatment of Psychotic Symptoms in Dementia Patients Unknown status NCT00190021 Phase 3 donepezil
10 Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension Terminated NCT02928445 Phase 2, Phase 3 RVT-101 35 mg;RVT-101 70 mg
11 A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase Completed NCT01278407 Phase 3 Donepezil 5 mg;Donepezil 10 mg;Donepezil matched placebo
12 Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies Completed NCT00230997 Phase 3 Galantamine
13 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
14 Oculomotor Testing in the Differential Diagnosis of Dementia Completed NCT01577394 Phase 3
15 Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine Not yet recruiting NCT03858270 Phase 3 Memantine
16 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
17 Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies Recruiting NCT03467152 Phase 2 E2027;Placebo
18 Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study Completed NCT02669433 Phase 2 RVT-101 35 mg;RVT-101 70 mg;Placebo
19 A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies Suspended NCT03592862 Phase 2 HTL0018318;Placebo
20 Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies Recruiting NCT03888222 Phase 2 Placebo Oral Tablet;Bosutinib Oral Tablet
21 Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia Completed NCT02640729 Phase 2 Nelotanserin;Placebo
22 A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies Completed NCT00598650 Phase 2 E2020
23 A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431) Completed NCT00543855 Phase 2 3 mg Donepezil hydrochloride;5 mg Donepezil hydrochloride;10 mg Donepezil hydrochloride;Placebo
24 Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB) Completed NCT00630500 Phase 2 Memantine;Placebo
25 A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) Recruiting NCT03305809 Phase 2 LY3154207;Placebo
26 Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Active, not recruiting NCT02702102 Phase 2 11C-PBR28
27 Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Terminated NCT02871427 Phase 2 Nelotanserin
28 Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) Completed NCT02708186 Phase 2 Nelotanserin;Placebo
29 Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia Completed NCT02910102 Phase 2 RVT-101 35 mg;Placebo
30 A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET) Completed NCT01503944 Phase 1, Phase 2 18F-AV-133;18F-AV-45
31 Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI) Active, not recruiting NCT02450786 Phase 2 Donepezil
32 A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Not yet recruiting NCT03538522 Phase 2 N-831(Traneurocin) 10 mg QD;NA-831 (Traneurocin) 20 mg QD;NA-831 (Traneurocin) 40 mg QD;Placebo oral capsule QD
33 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes Recruiting NCT03555292 Phase 2 11C-PiB
34 Therapy in Amyotrophic Lateral Sclerosis (TAME) Recruiting NCT02118727 Phase 2 Memantine;Placebo (for Memantine)
35 Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 Completed NCT02281474 Phase 1 Nilotinib
36 Nilotinib in Huntington's Disease Recruiting NCT03764215 Phase 1 Nilotinib 150 MG
37 Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease. Unknown status NCT01876459 Not Applicable
38 Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)) Unknown status NCT01993628 Not Applicable
39 Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies Unknown status NCT01256905 Not Applicable Armodafinil
40 Movement and Music Intervention for Individuals With Dementia Unknown status NCT03121950 Not Applicable
41 Gait and REM Sleep Behavior Disorder Unknown status NCT02554331 Not Applicable
42 Parkinson's Disease, Diagnostic Observations (PADDO) Unknown status NCT01249768
43 Understanding Hallucinations (Part II) Unknown status NCT02460965
44 Understanding Hallucinations (Part I) Unknown status NCT01907568
45 Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies Completed NCT00917709 Not Applicable
46 Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies Completed NCT01340001 Not Applicable
47 Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease Recruiting NCT03019757
48 A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease Completed NCT01944436 Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
49 Deep Brain Stimulation for Patients With Dementia With Lewy Bodies Completed NCT02263937 Not Applicable
50 Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI) Completed NCT00820937 Not Applicable

Search NIH Clinical Center for Dementia, Lewy Body

Cochrane evidence based reviews: lewy body disease

Genetic Tests for Dementia, Lewy Body

Genetic tests related to Dementia, Lewy Body:

# Genetic test Affiliating Genes
1 Lewy Body Dementia 30 GBA SNCA SNCB
2 Lewy Bodies 30

Anatomical Context for Dementia, Lewy Body

MalaCards organs/tissues related to Dementia, Lewy Body:

42
Brain, Testes, Heart, Eye, Colon, Cortex, Small Intestine

Publications for Dementia, Lewy Body

Articles related to Dementia, Lewy Body:

(show top 50) (show all 242)
# Title Authors Year
1
Brain Network and Abnormal Hemispheric Asymmetry Analyses to Explore the Marginal Differences in Glucose Metabolic Distributions Among Alzheimer's Disease, Parkinson's Disease Dementia, and Lewy Body Dementia. ( 31031697 )
2019
2
Parkinson's and Lewy body dementia CSF biomarkers. ( 31051162 )
2019
3
Structural correlates of attention dysfunction in Lewy body dementia and Alzheimer's disease: an ex-Gaussian analysis. ( 31006825 )
2019
4
Extreme sleep pattern in Lewy body dementia: a hypothalamic matter? ( 30852516 )
2019
5
86 Hyperfamiliarity for Unknown Faces in a Patient with Lewy Body Dementia. ( 30859999 )
2019
6
Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. ( 30867052 )
2019
7
Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis. ( 30783428 )
2019
8
Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia. ( 30775974 )
2019
9
Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial. ( 30658705 )
2019
10
Neuroimaging in Lewy body dementia. ( 29761296 )
2019
11
Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria. ( 30797240 )
2019
12
Dysfunctional brain dynamics and their origin in Lewy body dementia. ( 30938426 )
2019
13
Causes and outcomes of hospitalization in Lewy body dementia: A retrospective cohort study. ( 30930058 )
2019
14
Module differences of glucose metabolic brain network among Alzheimer's disease, Parkinson's disease dementia, Lewy body dementia and health control. ( 30440801 )
2018
15
Lewy Body Dementia. ( 30336990 )
2018
16
Machine learning identified an Alzheimer's disease-related FDG-PET pattern which is also expressed in Lewy body dementia and Parkinson's disease dementia. ( 30185806 )
2018
17
Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The DIAMOND Lewy study. ( 30091150 )
2018
18
Glucose Metabolic Brain Network Differences between Chinese Patients with Lewy Body Dementia and Healthy Control. ( 29854020 )
2018
19
Probable Lewy Body Dementia with a Predilection for Auditory Hallucinations. ( 30013866 )
2018
20
When Post-Traumatic Stress Disorder and Charles Bonnet Syndrome Become Lewy Body Dementia. ( 29778582 )
2018
21
Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia. ( 28988547 )
2018
22
Long reaction times are associated with delayed brain activity in lewy body dementia. ( 29094778 )
2018
23
Non-pharmacological interventions for Lewy body dementia: a systematic review. ( 29143692 )
2018
24
Clinical prevalence of Lewy body dementia. ( 29448953 )
2018
25
APOE DNA methylation is altered in Lewy body dementia. ( 29544979 )
2018
26
Electroencephalographic derived network differences in Lewy body dementia compared to Alzheimer's disease patients. ( 29545639 )
2018
27
Occipital and Cingulate Hypometabolism are Significantly Under-Reported on 18-Fluorodeoxyglucose Positron Emission Tomography Scans of Patients with Lewy Body Dementia. ( 29657900 )
2018
28
Patient with rapidly evolving neurological disease with neuropathological lesions of Creutzfeldt-Jakob disease, Lewy body dementia, chronic subcortical vascular encephalopathy and meningothelial meningioma. ( 27634418 )
2017
29
The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China. ( 26882509 )
2017
30
Effect of Vascular Risk Factors on the Progression of Mild Alzheimer's Disease and Lewy Body Dementia. ( 28035932 )
2017
31
ALBA Screening Instrument (ASI): A brief screening tool for Lewy Body Dementia. ( 28088604 )
2017
32
Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. ( 28269775 )
2017
33
Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer's disease. ( 28391039 )
2017
34
A descriptive study of Lewy body dementia with functional imaging support in a Chinese population: a preliminary study. ( 28473650 )
2017
35
MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia? ( 28705819 )
2017
36
Aripiprazole Improves Psychotic, Cognitive, and Motor Symptoms in a Patient With Lewy Body Dementia. ( 28806386 )
2017
37
Dextrometorphan-Paroxetine, But Not Dronabinol, Effective for Treatment-Resistant Aggression and Agitation in an Elderly Patient With Lewy Body Dementia. ( 29035934 )
2017
38
Neuroleptic Malignant Syndrome Caused by Quetiapine in an Elderly Man with Lewy Body Dementia. ( 27564641 )
2016
39
Effects of transcranial direct current stimulation upon attention and visuoperceptual function in Lewy body dementia: a preliminary study. ( 26250473 )
2016
40
Neural correlates of attention-executive dysfunction in lewy body dementia and Alzheimer's disease. ( 26705763 )
2016
41
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. ( 26938614 )
2016
42
A faster way to diagnose Lewy body dementia. ( 27062761 )
2016
43
Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. ( 27224930 )
2016
44
Exercise for Individuals with Lewy Body Dementia: A Systematic Review. ( 27258533 )
2016
45
Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. ( 27296778 )
2016
46
Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease. ( 27544062 )
2016
47
Paired Studies Comparing Clinical Profiles of Lewy Body Dementia with Alzheimer's and Parkinson's Diseases. ( 27567844 )
2016
48
Gene expression profiling of brain samples from patients with Lewy body dementia. ( 27666482 )
2016
49
High dose rivastigmine in the symptom management of Lewy body dementia. ( 27899389 )
2016
50
Contrasts Between Patients With Lewy Body Dementia Syndromes and APOE-ε3/ε3 Patients With Late-onset Alzheimer Disease Dementia. ( 26280289 )
2015

Variations for Dementia, Lewy Body

UniProtKB/Swiss-Prot genetic disease variations for Dementia, Lewy Body:

76
# Symbol AA change Variation ID SNP ID
1 SNCA p.Glu46Lys VAR_022703 rs104893875

ClinVar genetic disease variations for Dementia, Lewy Body:

6 (show all 29)
# Gene Variation Type Significance SNP ID Assembly Location
1 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant risk factor rs76763715 GRCh37 Chromosome 1, 155205634: 155205634
2 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant risk factor rs76763715 GRCh38 Chromosome 1, 155235843: 155235843
3 GBA NM_001005741.2(GBA): c.1297G> T (p.Val433Leu) single nucleotide variant Pathogenic/Likely pathogenic rs80356769 GRCh37 Chromosome 1, 155205563: 155205563
4 GBA NM_001005741.2(GBA): c.1297G> T (p.Val433Leu) single nucleotide variant Pathogenic/Likely pathogenic rs80356769 GRCh38 Chromosome 1, 155235772: 155235772
5 SNCA NM_000345.3(SNCA): c.157G> A (p.Ala53Thr) single nucleotide variant Pathogenic rs104893877 GRCh37 Chromosome 4, 90749300: 90749300
6 SNCA NM_000345.3(SNCA): c.157G> A (p.Ala53Thr) single nucleotide variant Pathogenic rs104893877 GRCh38 Chromosome 4, 89828149: 89828149
7 SNCA NM_000345.3(SNCA): c.136G> A (p.Glu46Lys) single nucleotide variant Pathogenic rs104893875 GRCh37 Chromosome 4, 90749321: 90749321
8 SNCA NM_000345.3(SNCA): c.136G> A (p.Glu46Lys) single nucleotide variant Pathogenic rs104893875 GRCh38 Chromosome 4, 89828170: 89828170
9 SNCA SNCA, DUPLICATION duplication Pathogenic
10 GBA NM_001005741.2(GBA): c.115+1G> A single nucleotide variant Pathogenic rs104886460 GRCh37 Chromosome 1, 155210420: 155210420
11 GBA NM_001005741.2(GBA): c.115+1G> A single nucleotide variant Pathogenic rs104886460 GRCh38 Chromosome 1, 155240629: 155240629
12 SNCA NM_000345.3(SNCA): c.408C> T (p.Tyr136=) single nucleotide variant Benign/Likely benign rs76642636 GRCh38 Chromosome 4, 89726643: 89726643
13 SNCA NM_000345.3(SNCA): c.408C> T (p.Tyr136=) single nucleotide variant Benign/Likely benign rs76642636 GRCh37 Chromosome 4, 90647794: 90647794
14 SNCA NC_000004.12: g.(?_89726164)_(89835687_?)dup duplication Pathogenic GRCh38 Chromosome 4, 89726164: 89835687
15 SNCA NC_000004.12: g.(?_89726164)_(89835687_?)dup duplication Pathogenic GRCh37 Chromosome 4, 90647315: 90756838
16 SNCB NM_001001502.2(SNCB): c.368C> A (p.Pro123His) single nucleotide variant Pathogenic rs104893937 GRCh38 Chromosome 5, 176621218: 176621218
17 SNCB NM_001001502.2(SNCB): c.368C> A (p.Pro123His) single nucleotide variant Pathogenic rs104893937 GRCh37 Chromosome 5, 176048219: 176048219
18 SNCB NM_001001502.2(SNCB): c.208G> A (p.Val70Met) single nucleotide variant Pathogenic rs104893936 GRCh38 Chromosome 5, 176626472: 176626472
19 SNCB NM_001001502.2(SNCB): c.208G> A (p.Val70Met) single nucleotide variant Pathogenic rs104893936 GRCh37 Chromosome 5, 176053473: 176053473
20 GBA NM_000157.3(GBA): c.1604G> A (p.Arg535His) single nucleotide variant Pathogenic rs75822236 GRCh38 Chromosome 1, 155235002: 155235002
21 GBA NM_000157.3(GBA): c.1604G> A (p.Arg535His) single nucleotide variant Pathogenic rs75822236 GRCh37 Chromosome 1, 155204793: 155204793
22 GBA NM_001005741.2(GBA): c.1504C> T (p.Arg502Cys) single nucleotide variant Pathogenic rs80356771 GRCh38 Chromosome 1, 155235196: 155235196
23 GBA NM_001005741.2(GBA): c.1504C> T (p.Arg502Cys) single nucleotide variant Pathogenic rs80356771 GRCh37 Chromosome 1, 155204987: 155204987
24 GBA NM_000157.3(GBA): c.1342G> C (p.Asp448His) single nucleotide variant Pathogenic/Likely pathogenic rs1064651 GRCh38 Chromosome 1, 155235727: 155235727
25 GBA NM_000157.3(GBA): c.1342G> C (p.Asp448His) single nucleotide variant Pathogenic/Likely pathogenic rs1064651 GRCh37 Chromosome 1, 155205518: 155205518
26 GBA NM_001005741.2(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs421016 GRCh38 Chromosome 1, 155235252: 155235252
27 GBA NM_001005741.2(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs421016 GRCh37 Chromosome 1, 155205043: 155205043
28 GBA NM_001005741.2(GBA): c.887G> A (p.Arg296Gln) single nucleotide variant Pathogenic rs78973108 GRCh38 Chromosome 1, 155237453: 155237453
29 GBA NM_001005741.2(GBA): c.887G> A (p.Arg296Gln) single nucleotide variant Pathogenic rs78973108 GRCh37 Chromosome 1, 155207244: 155207244

Expression for Dementia, Lewy Body

Search GEO for disease gene expression data for Dementia, Lewy Body.

Pathways for Dementia, Lewy Body

Pathways related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 APP MAOB PRKN RPS27A SLC18A2 SLC6A3
2
Show member pathways
13.25 APOE APP LRRK2 MAPT PARK7 PRKN
3
Show member pathways
12.53 PARK7 PRKN SLC6A3 SNCA SNCAIP
4 11.9 APOE APP LRRK2 MAPT PARK7 PRKN
5
Show member pathways
11.8 MAOB SLC18A2 SLC6A3 TH
6 11.77 APP CYP2D6 MAOB SLC18A2
7 11.62 LRRK2 PARK7 PRKN SLC6A3 SNCA SNCAIP
8 11.42 APP MAPT PRNP
9 11.32 APOE APP MAPT
10
Show member pathways
11.29 ACHE SLC6A3 TH
11 11.2 ACHE APOE CYP2D6
12 11.02 SLC18A2 SLC6A3 TH
13 10.94 MAOB PARK7 PRKN SLC6A3 SNCA TH
14
Show member pathways
10.93 ACHE BCHE SLC6A3
15 10.7 MAOB TH
16 10.63 PRKN RPS27A
17 10.62 ACHE TH

GO Terms for Dementia, Lewy Body

Cellular components related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.99 ACHE APP PARK7 PRKN SNCA SNCG
2 dendrite GO:0030425 9.96 APOE LRRK2 MAPT PRNP TH
3 neuron projection GO:0043005 9.87 APP LRRK2 MAPT PARK7 PRKN SLC6A3
4 mitochondrial outer membrane GO:0005741 9.83 LRRK2 MAOB RPS27A SNCA
5 postsynapse GO:0098794 9.8 LRRK2 PRNP SNCA
6 synaptic vesicle GO:0008021 9.77 LRRK2 SLC18A2 SNCA SNCAIP TH
7 growth cone GO:0030426 9.76 APP LRRK2 MAPT SNCA
8 synaptic vesicle membrane GO:0030672 9.74 LRRK2 SLC18A2 SNCA
9 presynapse GO:0098793 9.73 PARK7 PRKN SNCA SNCB
10 membrane raft GO:0045121 9.73 APP LRRK2 MAPT PARK7 PRNP SLC6A3
11 terminal bouton GO:0043195 9.71 LRRK2 SLC18A2 SNCA TH
12 synaptic cleft GO:0043083 9.6 ACHE APOE
13 dopaminergic synapse GO:0098691 9.59 SLC18A2 SLC6A3
14 neuronal cell body GO:0043025 9.56 APOE LRRK2 MAPT SLC6A3 SNCA SNCAIP
15 nuclear envelope lumen GO:0005641 9.55 APP BCHE
16 main axon GO:0044304 9.54 APP MAPT
17 inclusion body GO:0016234 9.46 LRRK2 PRNP SNCA SNCB
18 axon GO:0030424 9.23 APP LRRK2 MAPT PARK7 SLC6A3 SNCA
19 membrane GO:0016020 10.48 ACHE APOE APP BCHE CYP2D6 GBA
20 cytoplasm GO:0005737 10.35 APOE APP CYP2D6 LRRK2 MAPT PARK7
21 extracellular space GO:0005615 10.19 ACHE APOE APP BCHE GBA LRRK2
22 endoplasmic reticulum GO:0005783 10.16 APOE BCHE CYP2D6 LRRK2 PARK7 PRKN
23 Golgi apparatus GO:0005794 10.12 ACHE APOE APP LRRK2 PRKN PRNP
24 mitochondrion GO:0005739 10.1 CYP2D6 LRRK2 MAOB MAPT PARK7 PRKN
25 synapse GO:0045202 10.01 ACHE APP LRRK2 SNCA SNCB

Biological processes related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.97 APOE APP PRKN RPS27A SNCA SNCAIP
2 negative regulation of neuron apoptotic process GO:0043524 9.95 APOE PARK7 PRKN SNCA SNCB
3 response to ethanol GO:0045471 9.92 MAOB SLC6A3 TH
4 response to oxidative stress GO:0006979 9.91 APOE APP LRRK2 PRKN PRNP
5 cellular response to oxidative stress GO:0034599 9.9 LRRK2 PARK7 SNCA
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 APP PARK7 SNCA
7 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.88 GBA LRRK2 PRKN
8 mitochondrion organization GO:0007005 9.88 GBA LRRK2 PARK7 PRKN
9 locomotory behavior GO:0007626 9.88 APP PRKN SLC18A2 SLC6A3 TH
10 positive regulation of protein binding GO:0032092 9.86 APP LRRK2 PRKN
11 regulation of autophagy GO:0010506 9.86 LRRK2 MAPT PRKN
12 learning GO:0007612 9.86 APP BCHE PRKN TH
13 negative regulation of protein phosphorylation GO:0001933 9.83 LRRK2 PARK7 PRKN PRNP SNCA
14 protein destabilization GO:0031648 9.82 PRKN PRNP SNCA
15 positive regulation of neuron death GO:1901216 9.8 MAPT PRNP SNCA
16 regulation of dopamine secretion GO:0014059 9.78 PRKN SNCA SNCG
17 cellular response to copper ion GO:0071280 9.77 APP PRNP SNCA
18 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.75 LRRK2 PARK7 PRKN
19 microglial cell activation GO:0001774 9.74 MAPT SNCA
20 response to metal ion GO:0010038 9.74 SNCB TH
21 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.74 APP PRNP
22 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.74 LRRK2 PARK7
23 cellular copper ion homeostasis GO:0006878 9.74 APP PRNP
24 neurotransmitter biosynthetic process GO:0042136 9.74 ACHE SLC6A3 TH
25 cellular response to dopamine GO:1903351 9.73 LRRK2 PRKN
26 locomotory exploration behavior GO:0035641 9.73 APOE LRRK2
27 negative regulation of protein processing GO:0010955 9.73 LRRK2 PRNP
28 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.73 PARK7 SLC18A2
29 supramolecular fiber organization GO:0097435 9.73 MAPT SNCA
30 regulation of protein metabolic process GO:0051246 9.72 APOE GBA
31 amyloid precursor protein metabolic process GO:0042982 9.72 ACHE APOE
32 virion assembly GO:0019068 9.72 APOE RPS27A
33 adult locomotory behavior GO:0008344 9.72 APP PARK7 PRKN SNCA SNCG
34 astrocyte activation GO:0048143 9.71 APP MAPT
35 negative regulation of amyloid-beta formation GO:1902430 9.71 APOE PRNP
36 neuron projection maintenance GO:1990535 9.71 APP PRNP
37 neurotransmitter catabolic process GO:0042135 9.71 ACHE MAOB
38 positive regulation of protein metabolic process GO:0051247 9.71 APP GBA
39 dopamine biosynthetic process GO:0042416 9.71 SLC6A3 SNCA TH
40 regulation of neurotransmitter secretion GO:0046928 9.71 PRKN SNCA SNCAIP SNCG
41 regulation of dopamine metabolic process GO:0042053 9.7 PRKN SLC6A3
42 amyloid fibril formation GO:1990000 9.7 APP MAPT
43 intracellular distribution of mitochondria GO:0048312 9.7 LRRK2 MAPT
44 negative regulation of long-term synaptic potentiation GO:1900272 9.7 APOE APP PRNP
45 monoamine transport GO:0015844 9.69 SLC18A2 SLC6A3
46 positive regulation of microglial cell activation GO:1903980 9.69 APP LRRK2
47 regulation of locomotion GO:0040012 9.69 LRRK2 SNCA
48 dopamine catabolic process GO:0042420 9.68 MAOB SLC6A3
49 mating behavior GO:0007617 9.68 APP TH
50 regulation of mitochondrial fission GO:0090140 9.67 LRRK2 MAPT

Molecular functions related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.81 LRRK2 MAPT PRNP SNCA
2 chaperone binding GO:0051087 9.74 MAPT PRKN PRNP
3 enzyme binding GO:0019899 9.7 APP BCHE MAPT PARK7 PRKN SNCA
4 copper ion binding GO:0005507 9.65 PARK7 PRNP SNCA
5 identical protein binding GO:0042802 9.65 APOE APP BCHE LRRK2 MAPT PARK7
6 amyloid-beta binding GO:0001540 9.62 ACHE APOE BCHE PRNP
7 tau protein binding GO:0048156 9.58 APOE SNCA
8 ubiquitin-specific protease binding GO:1990381 9.56 PARK7 PRKN
9 tubulin binding GO:0015631 9.56 LRRK2 MAPT PRKN PRNP
10 phospholipase binding GO:0043274 9.55 PRKN SNCA
11 dopamine binding GO:0035240 9.54 SLC6A3 TH
12 monoamine transmembrane transporter activity GO:0008504 9.49 SLC18A2 SLC6A3
13 lipoprotein particle binding GO:0071813 9.46 APOE MAPT
14 cupric ion binding GO:1903135 9.43 PARK7 PRNP
15 cholinesterase activity GO:0004104 9.4 ACHE BCHE
16 acetylcholinesterase activity GO:0003990 9.37 ACHE BCHE
17 cuprous ion binding GO:1903136 8.92 PARK7 PRNP SNCA SNCB
18 protein homodimerization activity GO:0042803 10 ACHE APOE LRRK2 MAOB MAPT PARK7

Sources for Dementia, Lewy Body

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....